Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 8/20 | 0.48 |
| ▸ | HRH1 | P35367 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3376481 | 1.00 | HRH2 (0.48) | HRH2HRH1ALDH1A1KDM4EITGB3 | |
| SCHEMBL3376486 | 1.00 | HRH2 (0.48) | HRH2HRH1ALDH1A1KDM4EITGB3 | |
| SCHEMBL3815002 | 0.93 | PSMB1 (0.51) | HRH2HRH1ALDH1A1KDM4ELTA4H | |
| SCHEMBL4684742 | 0.92 | PSMB1 (0.53) | ALDH1A1KDM4ELTA4HMEN1KMT2A | |
| SCHEMBL4684740 | 0.92 | PSMB1 (0.53) | ALDH1A1KDM4ELTA4HMEN1KMT2A | |
| SCHEMBL31737696 | 0.92 | HRH2 (0.48) | HRH2HRH1ALDH1A1KDM4EITGB3 | |
| SCHEMBL3379563 | 0.90 | ALDH1A1 (0.53) | HRH2HRH1ALDH1A1KDM4ELTA4H | |
| SCHEMBL3379568 | 0.90 | ALDH1A1 (0.53) | HRH2HRH1ALDH1A1KDM4ELTA4H | |
| SCHEMBL3379566 | 0.90 | ALDH1A1 (0.53) | HRH2HRH1ALDH1A1KDM4ELTA4H | |
| SCHEMBL5084989 | 0.85 | ITGB3 (0.52) | HRH2HRH1ALDH1A1KDM4EITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989186-B1 | HYDANTOIN BASED KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-11-17 | — | — | EP | disclosed |
| US-7612212-B2 | 2-[(S)-2-((S)-2,5-dioxo-4-phenyl-imidazolidin-1-yl)-4-methyl-pentanoylamino]-thiazole-4-carboxylic acid methyl ester; mitogen activated protein/extracellular signal regulated kinase kinase inhibitor; anticarcinogenic agent, cognition activator, nervous and autoimmune system disorders | HOFFMANN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| WO-2008101840-A1 | COMBINATION OF ERLOTINIB AND MEK-INHIBITORS FOR INHIBITING PROLIFERATION OF TUMOR CELLS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| US-20080207563-A1 | METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS | NIU HUIFENG | 2008-08-28 | — | — | US | disclosed |
| US-20070197617-A1 | Substituted hydantoins | CHEN SHAOQING | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197617-A1 | Substituted hydantoins | HNMT, HRH3, BRAF | HRH2 37/4885HRH1 15/4885ALDH1A1 963/4885 |
| US-20080207563-A1 | METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS | MKI67, BRAF, MYC | HRH2 1693/4885HRH1 2431/4885ALDH1A1 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.